Characterising multilevel mechanisms of targeted radionuclide therapy
Radiotherapy of tumours has seen tremendous advances in the last several decades relative to the potentially cancer-causing and non-selective radiation of earlier years. Targeted radionuclide therapy (TRT), like chemotherapy, is a systemic treatment. It relies on a cancer cell-targeting molecule labelled with a radionuclide to deliver toxic radiation directly to the tumour site. While TRTs are very promising, optimising treatments requires better understanding of their specific radiobiological effects. The EU-funded RADIOBIO project will yield critical information on subcellular and intratumoural radiopharmaceutical uptake kinetics, DNA damage response kinetics and dose response simulations while delivering a novel imaging technique to image real-time cellular processes of anti-cancer therapies in a living organism.
Fields of science
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Call for proposalSee other projects for this call
Funding SchemeHORIZON-AG - HORIZON Action Grant Budget-Based
3015 GD Rotterdam
See on map